Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Description of a knock-in mouse model of JAK2V617F MPN emerging from a minority of mutated hematopoietic stem cells.

Mansier O, Kilani B, Guitart AV, Guy A, Gourdou-Latyszenok V, Marty C, Parrens M, Plo I, Vainchenker W, James C.

Blood. 2019 Dec 26;134(26):2383-2387. doi: 10.1182/blood.2019001163.

PMID:
31697834
2.

High circulating levels of MPO-DNA are associated with thrombosis in patients with MPN.

Guy A, Favre S, Labrouche-Colomer S, Deloison L, Gourdou-Latyszenok V, Renault MA, Riviere E, James C.

Leukemia. 2019 Oct;33(10):2544-2548. doi: 10.1038/s41375-019-0500-2. Epub 2019 Jun 7. No abstract available.

PMID:
31175322
3.

Comparison of endothelial promoter efficiency and specificity in mice reveals a subset of Pdgfb-positive hematopoietic cells.

Kilani B, Gourdou-Latyszenok V, Guy A, Bats ML, Peghaire C, Parrens M, Renault MA, DuplĂ a C, Villeval JL, Rautou PE, Couffinhal T, James C.

J Thromb Haemost. 2019 May;17(5):827-840. doi: 10.1111/jth.14417. Epub 2019 Mar 24.

PMID:
30801958
4.

Vascular endothelial cell expression of JAK2V617F is sufficient to promote a pro-thrombotic state due to increased P-selectin expression.

Guy A, Gourdou-Latyszenok V, Le Lay N, Peghaire C, Kilani B, Dias JV, Duplaa C, Renault MA, Denis C, Villeval JL, Boulaftali Y, Jandrot-Perrus M, Couffinhal T, James C.

Haematologica. 2019 Jan;104(1):70-81. doi: 10.3324/haematol.2018.195321. Epub 2018 Aug 31.

Supplemental Content

Loading ...
Support Center